Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Winnie W Y Yeung

Showing results (1-10 of 4) with videos related to

Pageof 1
Sort By:
Asia Pacific Allergy|February 17, 2022
Delayed-type drug eruption to phenazopyridine (pyridium) confirmed with patch testingWinnie W Y Yeung, Christina S M Wong, Wai-Yan Leung, et al.
JAMA Network Open|June 26, 2024
Cost-Effectiveness of Biosimilars vs Leflunomide in Patients With Rheumatoid ArthritisKuan Peng, Shirley C W Chan, Yang Wang, et al.
Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy|March 23, 2023
Impact of Introducing Infliximab Biosimilars on Total Infliximab Consumption and Originator Infliximab Prices in Eight Regions: An Interrupted Time-Series AnalysisKuan Peng, Joseph E Blais, Nicole L Pratt, et al.
Frontiers in Immunology|July 3, 2023
Risk and Factors associated with disease manifestations in systemic lupus erythematosus - lupus nephritis (RIFLE-LN): a ten-year risk prediction strategy derived from a cohort of 1652 patientsShirley C W Chan, Yong-Fei Wang, Desmond Y H Yap, et al.
Pageof 1

Showing results (1-10 of 4) with videos related to

Sort By:
Pageof 1
Asia Pacific Allergy|February 17, 2022
Delayed-type drug eruption to phenazopyridine (pyridium) confirmed with patch testingWinnie W Y Yeung, Christina S M Wong, Wai-Yan Leung, et al.
JAMA Network Open|June 26, 2024
Cost-Effectiveness of Biosimilars vs Leflunomide in Patients With Rheumatoid ArthritisKuan Peng, Shirley C W Chan, Yang Wang, et al.
Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy|March 23, 2023
Impact of Introducing Infliximab Biosimilars on Total Infliximab Consumption and Originator Infliximab Prices in Eight Regions: An Interrupted Time-Series AnalysisKuan Peng, Joseph E Blais, Nicole L Pratt, et al.
Frontiers in Immunology|July 3, 2023
Risk and Factors associated with disease manifestations in systemic lupus erythematosus - lupus nephritis (RIFLE-LN): a ten-year risk prediction strategy derived from a cohort of 1652 patientsShirley C W Chan, Yong-Fei Wang, Desmond Y H Yap, et al.
Pageof 1